-+ 0.00%
-+ 0.00%
-+ 0.00%
The $10.6 billion acquisition ushered in a key return! GlaxoSmithKline (GSK.US)'s new lung cancer drug Nelkarmi approved for listing on the billion dollar market
Share
Listen to the news

The Zhitong Finance App learned that neladalkib, a lung cancer drug owned by GSK.US (GSK.US), was approved for marketing by the US Food and Drug Administration (FDA), providing new treatment options for patients whose condition is still progressing after receiving ALK targeted treatment, further verifying the strategic value of the British pharmaceutical company's previous acquisition of biotech company Nuvalent.

The drug will be marketed under the Nelkarmi brand name and approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) driven by ALK gene mutations. Specifically, the target group includes patients who have been treated with an ALK tyrosine kinase inhibitor (TKI) alectinib (alectinib) in the stage of unresectable locally advanced or metastatic disease, or who have received two or more ALK TKI and platinum chemotherapy. ALK gene abnormalities cause abnormal cell growth and are an important causative factor in some non-small cell lung cancers.

Nelkarmi has now received accelerated approval from the US, mainly based on data obtained during its phase I/II ALKOVE-1 clinical trial. The trial is a multi-center, open-label study to evaluate the efficacy and safety of Neldalkib in advanced ALK-positive non-small cell lung cancer patients who have previously received ALK-targeted therapy. A total of 222 patients were included in the main efficacy analysis to support FDA approval. Of these, 67 patients had previously only received aletinib treatment, while another 155 patients had previously received two or more ALK TKIs and platinum chemotherapy.

Test results showed that the confirmed objective remission rate (ORR) of Nelkarmi reached 49% among patients who had previously received only aletinib; among patients who had previously received two or more ALK TKI and platinum chemotherapy, the objective remission rate was 32%. Looking at the duration of remission (DOR), in the first group of patients, 76% of those in remission achieved or longer than 6 months, and 52% achieved or more than 12 months; the corresponding proportion of patients in the latter group was 69% and 51%, respectively.

What is more noteworthy is that this drug has also shown certain curative effects in patients with brain metastases. Among patients with measurable central nervous system (CNS) metastases at baseline, patients who had previously received only alentinib had an objective intracranial remission rate of 55%, of which the complete remission rate was 25%; patients who had previously received two or more ALK TKI and platinum chemotherapy had an objective intracranial remission rate of 26%, of which the complete remission rate was 11%. This means that Nelkarmi is expected to provide new solutions to common brain metastases and drug resistance problems in ALK-positive lung cancer patients.

In terms of safety, the most common adverse effects include liver toxicity, musculoskeletal pain, constipation, taste disorder, peripheral neuropathy, oedema, and fatigue. The proportion of patients who permanently discontinued the drug due to adverse reactions was 5%.

Compared with existing ALK-targeted drugs, NelKarmi uses a new generation of highly selective ALK inhibitor designs to cover a wider range of ALK resistant mutations and improve the ability of drugs to penetrate the blood-brain barrier to address clinical challenges such as brain lesions and therapeutic drug resistance. However, at present, its full efficacy still needs to be further verified. GlaxoSmithKline is conducting a phase III clinical trial called ALKAZAR to evaluate the efficacy of the drug as a first-line treatment for ALK-positive non-small cell lung cancer and compare it with the existing standard treatment aletinib.

Investors have high hopes for this drug. Prior to the drug's approval, Jefferies analyst Michael Leuten said in a report to clients that Nelkarmi had “significant upside potential” until 2030 and beyond. Analysts surveyed by the media expect the drug's sales to reach around $1 billion in 2023.

The acquisition of Nuvent is an important part of GlaxoSmithKline's strategy to expand its oncology product portfolio under new CEO Luke Mills. Currently, Mills is under pressure to reinvigorate the company's R&D pipeline — many investors believe GlaxoSmithKline's R&D pipeline has failed to keep up with competitors. Earlier this year, GlaxoSmithKline bought Nuvalent for $10.6 billion and closed the deal in July of this year. It is also the company's largest acquisition deal to date.

From a strategic perspective, the core value of this deal is that GlaxoSmithKline obtained two next-generation precisely targeted lung cancer drugs at one time, which are in the late stages of clinical development and have significant drug potential, as well as a series of earlier R&D assets.

Among them, in addition to the ALK-targeted drug Neldalkib corresponding to nelKarmi, another drug, zidesamtinib (trade name Jideytro), is a next-generation ROS1 selective inhibitor. It was approved by the FDA in July this year to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer patients who have previously been treated with ROS1 kinase inhibitors. The drug also aims to address issues such as drug-resistant mutations, brain metastases, and treatment tolerability faced by existing treatments.

In addition, Nuvalent also has a HER2-targeted drug, NVL-330, which is in phase I clinical trials, and several pre-clinical research projects. This means that through this acquisition, GlaxoSmithKline has not only obtained two innovative lung cancer drugs that can be commercialized relatively quickly, but has also further improved its research and development market on key carcinogenic targets such as ALK, ROS1, and HER2, providing a new platform for future expansion of the lung cancer treatment market.

Notably, the deal is also expected to help GlaxoSmithKline accelerate its return to the oncology drug market. The company previously divested its oncology business and has since gradually rebuilt its product portfolio through a series of acquisitions and partnerships. With two Nuvalent drugs successively approved by the FDA, GlaxoSmithKline already has new commercial products in the field of lung cancer, which is expected to increase the share of the oncology business in overall revenue through the growth of the targeted treatment market.

Looking at the commercial outlook, GlaxoSmithKline previously stated that both of Nuvent's core drugs have the potential to become multiple blockbuster drugs (multi-blockbuster). Jefferies analysts expect the combined peak sales of these two drugs to reach $5 billion to $7 billion in the future. If the relevant expectations are fulfilled, this $10.6 billion acquisition is expected to become an important growth engine for GlaxoSmithKline in the next few years, and help the company cope with the patent expiration pressure faced by some existing drugs in the future.

“I think we are making excellent progress in our oncology product portfolio,” said Hirsham Abdullah, GlaxoSmithKline's head of oncology research and development at a briefing. He said that the company is building a lung cancer drug product line, and other drugs for diseases such as hematologic cancer and gastrointestinal cancer are in the development stage.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending